CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 80.96% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

TherapeuticsMD Q3 license revenue jumps 61% on IMVEXXY milestone payment

By Reuters News


Overview

  • US pharmaceutical royalty firm's Q3 license revenue rose 61% yr/yr on IMVEXXY milestone payment

  • Net income from continuing operations increased to $501,000 from $50,000 a year earlier


Outlook

  • Company to recognize IMVEXXY sales milestone revenue in Q4 2026

  • TherapeuticsMD continues to evaluate strategic alternatives, including potential mergers or asset sales


Result Drivers

  • IMVEXXY MILESTONE PAYMENT - Q3 license revenue rose due to a $365,000 milestone payment from Knight for IMVEXXY sales

  • HIGHER LEGAL FEES - Operating expenses increased mainly due to higher legal and professional fees


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Net Income from Cont Ops

$501,000

Q3 Operating Expenses

$1.70 mln


Reuters Recommended Reads

  • Nov 12 - Pfizer to stop selling Premarin hormone therapy in Canada

  • Nov 12 - Ascendis Pharma Q3 product revenue rises on YORVIPATH sales

  • Nov 12 - Israeli dermatology firm Sol-Gel's Q3 net loss narrows on lower R&D expenses


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.